BlinkLab Ltd
BlinkLab Limited is an Australia-based digital healthcare company focused on Artificial intelligence (AI) powered diagnostics.
The business
BlinkLab Limited is an Australia-based digital healthcare company focused on Artificial intelligence (AI) powered diagnostics. The Company has fully developed a smartphone based diagnostic platform for autism, Attention-Deficit/Hyperactivity Disorder (ADHD), schizophrenia, and other neurodevelopmental conditions. Its product is an autism diagnostic test that leverages the power of smartphones, AI and machine learning to deliver screening tests specifically designed for children as young as over 18 months old. Its pipeline includes BlinkLab Dx 1 and BlinkLab Dx N. Its BlinkLab Dx 1 is an autism diagnostic adjunct. Its BlinkLab Dx N is an ADHD diagnostic adjunct.
Small Caps Research
No research on BlinkLab Ltd yet
We cover the ASX small-cap market one company at a time. Request coverage and we’ll prioritise BB1 based on demand.
Share price
Market Statistics
Valuation
Trading Activity
Performance
Latest news
BlinkLab Dx 1 Device Pilot Study Confirms High Diagnostic Accuracy and Readiness for FDA Trial
BlinkLab (ASX: BB1) has completed a US pilot study evaluating the smartphone-based Dx 1 diagnostic device for the assessment of behavioural and developmental concerns in children, including autism spectrum disorder and attention deficit hyperactivity disorder. The unblinded study involved 485 clinically-diverse children aged between 2 years and 11 years, representing the full spectrum of developmental concerns, […]
BlinkLab partners with INTER-PSY to improve wait times for autism diagnosis in children
Digital healthcare company BlinkLab (ASX: BB1) has formed a research and clinical partnership with Netherlands-based INTER-PSY to improve wait times for autism diagnosis in children. INTER-PSY offers mental health care, guidance and diagnosis to children and adults with psychological and psychiatric conditions. The partnership will support the adoption of BlinkLab as a diagnostic tool within […]
BlinkLab to advance smartphone-neurobehavioural testing following IPO and ASX debut
Neuroscientist-led start-up BlinkLab (ASX: BB1) has made its Australian Securities Exchange (ASX) debut today after an oversubscribed initial public offering raised $7 million to advance a diagnostic tool for neurodevelopmental disorders. The company has committed to the issue of 35 million shares at $0.20 each for an undiluted market capitalisation of $19.8m on listing. The […]
Looking for charts & signals? See the tab.
Unlock the full research library - free.
Create a free account to access every broker report, CEO interview, IPO alert, and daily market wrap. No credit card. No paywall.